Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 408 (2) , 112879
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell'istruzione dell'università e della ricerca
- Istituto Pasteur-Fondazione Cenci Bolognetti
- Associazione Italiana per la Ricerca sul Cancro
This publication has 27 references indexed in Scilit:
- PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulationOncotarget, 2017
- Mutant p53 establishes targetable tumor dependency by promoting unscheduled replicationJournal of Clinical Investigation, 2017
- Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4Proceedings of the National Academy of Sciences, 2015
- Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARPMolecular Cancer Research, 2014
- Ionizing Radiation-Induced DNA Damage, Response, and RepairAntioxidants & Redox Signaling, 2014
- DNA Damage Sensing by the ATM and ATR KinasesCold Spring Harbor Perspectives in Biology, 2013
- Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentCell Cycle, 2011
- p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA DamageCancer Research, 2011
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Tumor Suppressor p53 Is Required To Modulate BRCA1 ExpressionMolecular and Cellular Biology, 2000